It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EOLS’s FA Score shows that 0 FA rating(s) are green whileLFCR’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EOLS’s TA Score shows that 4 TA indicator(s) are bullish while LFCR’s TA Score has 6 bullish TA indicator(s).
EOLS (@Pharmaceuticals: Other) experienced а -11.48% price change this week, while LFCR (@Pharmaceuticals: Other) price change was -5.04% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -5.07%. For the same industry, the average monthly price growth was -7.87%, and the average quarterly price growth was -11.90%.
EOLS is expected to report earnings on Feb 26, 2025.
LFCR is expected to report earnings on Jan 02, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
EOLS | LFCR | EOLS / LFCR | |
Capitalization | 847M | 177M | 479% |
EBITDA | -41.81M | -22.64M | 185% |
Gain YTD | 15.005 | 3.393 | 442% |
P/E Ratio | N/A | N/A | - |
Revenue | 202M | 188M | 107% |
Total Cash | 62.8M | 4.22M | 1,487% |
Total Debt | 127M | 157M | 81% |
EOLS | LFCR | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 59 | 22 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 95 Overvalued | 92 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 96 | |
PRICE GROWTH RATING 1..100 | 64 | 40 | |
P/E GROWTH RATING 1..100 | 100 | 7 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LFCR's Valuation (92) in the Industrial Specialties industry is in the same range as EOLS (95) in the Pharmaceuticals Major industry. This means that LFCR’s stock grew similarly to EOLS’s over the last 12 months.
LFCR's Profit vs Risk Rating (100) in the Industrial Specialties industry is in the same range as EOLS (100) in the Pharmaceuticals Major industry. This means that LFCR’s stock grew similarly to EOLS’s over the last 12 months.
LFCR's SMR Rating (96) in the Industrial Specialties industry is in the same range as EOLS (100) in the Pharmaceuticals Major industry. This means that LFCR’s stock grew similarly to EOLS’s over the last 12 months.
LFCR's Price Growth Rating (40) in the Industrial Specialties industry is in the same range as EOLS (64) in the Pharmaceuticals Major industry. This means that LFCR’s stock grew similarly to EOLS’s over the last 12 months.
LFCR's P/E Growth Rating (7) in the Industrial Specialties industry is significantly better than the same rating for EOLS (100) in the Pharmaceuticals Major industry. This means that LFCR’s stock grew significantly faster than EOLS’s over the last 12 months.
EOLS | LFCR | |
---|---|---|
RSI ODDS (%) | 3 days ago77% | 3 days ago79% |
Stochastic ODDS (%) | 3 days ago66% | 3 days ago79% |
Momentum ODDS (%) | 3 days ago87% | 3 days ago68% |
MACD ODDS (%) | N/A | 3 days ago67% |
TrendWeek ODDS (%) | 3 days ago83% | 3 days ago78% |
TrendMonth ODDS (%) | 3 days ago82% | 3 days ago72% |
Advances ODDS (%) | 12 days ago80% | 5 days ago74% |
Declines ODDS (%) | 4 days ago80% | 3 days ago78% |
BollingerBands ODDS (%) | 3 days ago71% | 3 days ago80% |
Aroon ODDS (%) | 3 days ago76% | 3 days ago74% |
A.I.dvisor tells us that EOLS and AMPH have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EOLS and AMPH's prices will move in lockstep.
Ticker / NAME | Correlation To EOLS | 1D Price Change % | ||
---|---|---|---|---|
EOLS | 100% | +1.94% | ||
AMPH - EOLS | 30% Poorly correlated | -1.00% | ||
ACET - EOLS | 26% Poorly correlated | -9.82% | ||
EVOK - EOLS | 26% Poorly correlated | +4.91% | ||
SNDL - EOLS | 25% Poorly correlated | N/A | ||
LFCR - EOLS | 23% Poorly correlated | -4.19% | ||
More |
A.I.dvisor tells us that LFCR and SHPH have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LFCR and SHPH's prices will move in lockstep.
Ticker / NAME | Correlation To LFCR | 1D Price Change % | ||
---|---|---|---|---|
LFCR | 100% | -4.19% | ||
SHPH - LFCR | 31% Poorly correlated | -6.82% | ||
CRON - LFCR | 29% Poorly correlated | -2.90% | ||
CGC - LFCR | 28% Poorly correlated | -0.27% | ||
TLRY - LFCR | 27% Poorly correlated | -2.17% | ||
OGI - LFCR | 26% Poorly correlated | -4.00% | ||
More |